HYPR
NASDAQHyperfine Inc.
News · 26 weeks46+200%
2026-03-012026-08-23
Mix1290d
- Other5(42%)
- Insider3(25%)
- Earnings2(17%)
- SEC Filings2(17%)
Latest news
25 items- INSIDERChief Operating Officer Teisseyre Thomas sold $6,273 worth of shares (7,345 units at $0.85), decreasing direct ownership by 1% to 671,256 units (SEC Form 4) to cover withholding tax4 - Hyperfine, Inc. (0001833769) (Issuer)
- INSIDERCFO and CAO Hale Brett sold $6,273 worth of shares (7,345 units at $0.85), decreasing direct ownership by 1% to 592,420 units (SEC Form 4) (tax withholding)4 - Hyperfine, Inc. (0001833769) (Issuer)
- PRHyperfine Announces FDA Clearance of the Next Optive AI™ Software, Further Enhancing Image Quality, Clinical Utility, and Ease of Use of the Swoop® System Across Care SettingsThis newest software delivers improved image quality across Swoop system sequences, a more intuitive scanning experience, and new foundational isotropic imaging designed to strengthen the clinical utility of portable MRI. Hyperfine, Inc. (NASDAQ:HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared AI-powered portable MRI system for the brain—the Swoop® system—today announced that it has received FDA clearance for its latest Optive AI™ software update. This advancement is Hyperfine’s second FDA-cleared software package since the launch of its next-generation Swoop system in mid-2025. It builds on Hyperfine’s Optive AI software to d
- SECSEC Form 10-Q filed by Hyperfine Inc.10-Q - Hyperfine, Inc. (0001833769) (Filer)
- SECHyperfine Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Hyperfine, Inc. (0001833769) (Filer)
- PRHyperfine, Inc. Reports Second Quarter 2026 Financial ResultsHyperfine, Inc. (NASDAQ:HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared AI-powered portable magnetic resonance (MR) brain imaging system—the Swoop® system—today announced second quarter 2026 financial results and provided a business update. "Q2 was another strong quarter for Hyperfine, marked by solid growth in placements and revenue, continued gross margin expansion, disciplined operating expense management, and a strengthened balance sheet. One year into the launch of the next-generation Swoop® system and our entry into the neurology office market, we are seeing broader use across care settings and international markets. We
- PRHyperfine Announces the Release of Multiple Peer-Reviewed Publications, Expanding Clinical Evidence for the Swoop® System Across a Growing Number of Sites of CareRecent publications in the prominent Journal of Neurosurgery and Stroke provide new evidence supporting the clinical value of the Swoop system in stroke care and neurosurgical settings. Hyperfine, Inc. (NASDAQ:HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared AI-powered portable MRI system for the brain—the Swoop® system—today announced the release of multiple peer-reviewed publications in the Journal of Neurosurgery and in Stroke, building evidence to support the value of the low field portable MRI in the neurosurgical and stroke treatment sites of care. The July 2026 issue of the Journal of Neurosurgery featured cases perfo
- PRHyperfine, Inc. to Announce Second Quarter 2026 Financial Results on August 6, 2026Hyperfine, Inc. (NASDAQ:HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared AI-powered portable MRI system for the brain—the Swoop® system—today announced that it will report financial results for the second quarter 2026 on Thursday, August 6, 2026. Management will host a corresponding conference call at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. A live audio webcast and an archive of the recording will be available through the Investors page of Hyperfine, Inc.’s corporate website at https://investors.hyperfine.io/. Participants are encouraged to register more than 15 minutes before the start of the call. For more informa
- PRHyperfine Announces European Launch of Next-Generation Swoop® SystemHyperfine has initiated the launch of the next-generation Swoop® system in European markets, beginning the global expansion of its most advanced portable MRI technology. Hyperfine, Inc. (NASDAQ:HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared AI-powered portable MRI system for the brain—the Swoop® system—today announced the European launch of the next-generation Swoop® system powered by the latest advancement in Optive AI™ software. This marks a significant milestone in the company’s global expansion of its most advanced portable MRI technology, supporting international commercial growth and improving global access to high-qua
- PRHyperfine Forms Global Neurosurgery Advisory Council to Support Expansion of Portable MRI in Neurosurgical CareLeading neurosurgeons from around the world will help guide the role of the Swoop® system in neurosurgical care, including surgical workflow, product capabilities, and clinical evidence. Hyperfine, Inc. (NASDAQ:HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared AI-powered portable MRI system for the brain—the Swoop® system—today announced the formation of its Neurosurgery Advisory Council, a multidisciplinary group of leading neurosurgeons who will provide expertise to help inform the potential role of portable ultra-low-field MRI in neurosurgical applications and shape the future of imaging in neurosurgical care. "The neurosu
- PRHyperfine Swoop® System Scan Volume in the United States Hits Record Milestones Across Multiple Sites of CareRoutine clinical use is accelerating, driven by advanced image quality, expanding clinical utility, and increasingly diverse use cases across hospital and office settings. Hyperfine, Inc. (NASDAQ:HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared AI-powered portable MRI system for the brain—the Swoop® system—today announced the achievement of scan volume milestones in key hospitals and neurology clinics, demonstrating accelerating clinical utilization and adoption of the Swoop® system throughout the United States. The increasing clinical use of the Swoop® system is driven by several factors: enhanced clinical utility from impr
- INSIDERSEC Form 4 filed by Director Wolterman Dan4 - Hyperfine, Inc. (0001833769) (Issuer)
- INSIDERCFO and CAO Hale Brett sold $9,978 worth of shares (6,047 units at $1.65), decreasing direct ownership by 1.00% to 599,765 units (SEC Form 4)4 - Hyperfine, Inc. (0001833769) (Issuer)
- INSIDERChief Operating Officer Teisseyre Thomas sold $9,978 worth of shares (6,047 units at $1.65), decreasing direct ownership by 0.88% to 678,601 units (SEC Form 4) (withholding obligation)4 - Hyperfine, Inc. (0001833769) (Issuer)
- PRHyperfine to Join Russell 2000® and Russell 3000® IndexesHyperfine, Inc. (NASDAQ:HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared AI-powered portable MRI system for the brain—the Swoop® system— today announced that Hyperfine is expected to join the broad-market Russell 3000® Index and the small-cap Russell 2000® Index at the conclusion of the June 2026 Russell Reconstitution, according to a preliminary list of additions posted by FTSE Russell on May 22, 2026. Hyperfine's inclusion will become effective after the U.S. market close on June 26, 2026. The June reconstitution of the Russell US indexes captures up to the 4,000 largest U.S. stocks as of April 30, ranking them by total mark
- INSIDERSEC Form 4 filed by Director Fattori Ruth A4 - Hyperfine, Inc. (0001833769) (Issuer)
- INSIDERSEC Form 4 filed by Director Wolterman Dan4 - Hyperfine, Inc. (0001833769) (Issuer)
- INSIDERSEC Form 4 filed by Director Dahldorf John T4 - Hyperfine, Inc. (0001833769) (Issuer)
- INSIDERSEC Form 4 filed by Director Rothberg Jonathan M4 - Hyperfine, Inc. (0001833769) (Issuer)
- PRHyperfine Announces Presentation of Results from the PRIME Study Showing Portable MRI Substantially Reduces Time to Imaging in Emergency DepartmentsProspective randomized ED study shows rapid bedside imaging, detection of critical neurological findings, and potential workflow efficiency benefits with portable MRI Hyperfine, Inc. (NASDAQ:HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared AI-powered portable MRI system for the brain—the Swoop® system—today announced the presentation of results of the PRIME (Portable Rapid Imaging for Medical Emergencies) study at the Society for Academic Emergency Medicine (SAEM) 2026 Annual Meeting. PRIME is a single-center, prospective, randomized controlled trial designed to evaluate the role of portable MRI in neurological emergencies i
- SECSEC Form EFFECT filed by Hyperfine Inc.EFFECT - Hyperfine, Inc. (0001833769) (Filer)
- SECHyperfine Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - Hyperfine, Inc. (0001833769) (Filer)
- SECSEC Form S-3 filed by Hyperfine Inc.S-3 - Hyperfine, Inc. (0001833769) (Filer)
- SECSEC Form 10-Q filed by Hyperfine Inc.10-Q - Hyperfine, Inc. (0001833769) (Filer)
- SECHyperfine Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Hyperfine, Inc. (0001833769) (Filer)
HYPR FAQ
7 questionsWhat does Hyperfine Inc. do?
Hyperfine, Inc. provides imaging, monitoring, and magnetic resonance imaging products. It offers Swoop Portable MR imaging system to address an unmet need in point-of-care medical imaging through a combination of hardware and software services. The company was incorporated in 2014 and is based in Guilford, Connecticut.Where does HYPR stock trade?
Hyperfine Inc. (HYPR) is listed on NASDAQ.What sector and industry is HYPR in?
Hyperfine Inc. operates in the Health Care sector, Biotechnology: Electromedical & Electrotherapeutic Apparatus industry.When did Hyperfine Inc. go public?
Hyperfine Inc. (HYPR) completed its IPO in 2021.What are analysts saying about HYPR?
Hyperfine Inc. has had 4 recent analyst actions on file. The most recent action was from BTIG Research: Buy with a $200.00 price target on 2026-04-29. Recent price targets range from $200.00 to $800.00.What companies are similar to HYPR?
Notable peers in the same industry include MDT (Medtronic plc.), MASI (Masimo Corporation), SEAS (SeaWorld Entertainment Inc.), LIVN (LivaNova PLC), ITGR (Integer Holdings Corporation). Compare HYPR side-by-side with any of them on Quantisnow.How can I track HYPR on Quantisnow?
Quantisnow aggregates Hyperfine Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow HYPR to receive live email and push alerts on every new disclosure.